Kazuki Nozawa, Medical oncologist, shared a post on X:
“A phase II trial using Signatera ctDNA to guide CDK4/6 inhibitor use in HR⁺/HER2⁻ early breast cancer – treating only when molecular relapse appears.”
Read the Full Article.
More posts about Breast Cancer.